This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 2001;285:153-155.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

San Francisco—An experimental cancer therapy is expected to dramatically change the way clinicians treat patients with chronic myelogenous leukemia (CML), according to researchers presenting the latest findings from phase 2 trials involving more than 1000 patients with the disease.

The new findings, as well as results from other studies reported here at the annual meeting of the American Society of Hematology (ASH), reveal that an ever more sophisticated understanding of genetic and cellular mechanisms is beginning to bear fruit in the form of new therapeutic approaches for a wide range of disorders, from cancer to hemophilia to heart disease.

TARGETED LEUKEMIA DRUG

At the 1999 meeting, researchers reported the results of the first phase 1 study of STI571, an experimental drug that was tested in 61 patients with chronic-phase CML who did not respond to interferon treatment. All 31 patients who had received doses of at . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?